Verona Pharma PLC ADR

Company Profile

Verona Pharma PLC ADR had its IPO on 2017-04-27 under the ticker symbol VRNA.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Verona Pharma PLC ADR has a staff strength of 0 employees.

Stock update

Shares of Verona Pharma PLC ADR opened at $13.35 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $12.73 - $13.6, and closed at $12.97.

This is a -1.71% slip from the previous day's closing price.

A total volume of 360,921 shares were traded at the close of the day’s session.

In the last one week, shares of Verona Pharma PLC ADR have increased by +17.86%.

Verona Pharma PLC ADR's Key Ratios

Verona Pharma PLC ADR has a market cap of $0.790 billion, indicating a price to book ratio of 7.04 and a price to sales ratio of 19.76.

In the last 12-months Verona Pharma PLC ADR’s revenue was $0.040 billion with a gross profit of $0.040 billion and an EBITDA of $-0.050 billion. The EBITDA ratio measures Verona Pharma PLC ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Verona Pharma PLC ADR’s operating margin was -127.6% while its return on assets stood at -17.1% with a return of equity of -41.3%.

In Q2, Verona Pharma PLC ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Verona Pharma PLC ADR’s PE and PEG Ratio

Forward PE

-

Trailing PE

-

PEG

0

Its diluted EPS in the last 12-months stands at $-0.993 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Verona Pharma PLC ADR’s profitability.

Verona Pharma PLC ADR stock is trading at a EV to sales ratio of 16.86 and a EV to EBITDA ratio of -12.54. Its price to sales ratio in the trailing 12-months stood at 19.76.

Verona Pharma PLC ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$0.000 billion

Total Liabilities

$0.000 billion

Operating Cash Flow

$0.000 billion

Capital Expenditure

$0.000 billion

Dividend Payout Ratio

0%

Verona Pharma PLC ADR ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Verona Pharma PLC ADR ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Verona Pharma PLC ADR’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Verona Pharma PLC ADR's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Verona Pharma PLC ADR paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price

$12.97

52-Week High

$14.69

52-Week Low

$3.408

Analyst Target Price

$26

Verona Pharma PLC ADR stock is currently trading at $12.97 per share. It touched a 52-week high of $14.69 and a 52-week low of $14.69. Analysts tracking the stock have a 12-month average target price of $26.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.